TET2 is an enzyme that helps erase methyl marks from DNA so genes can be switched back on. Losing it is one of the commonest first steps toward blood cancer; mutant IDH blocks it indirectly, which is part of how ivosidenib works when it restores normal maturation. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Mutant IDH1 converts alpha-ketoglutarate to the oncometabolite 2-hydroxyglutarate, TET2 and histone demethylases lose activity, and blasts stop maturing; ivosidenib shuts off 2-HG production and TET2 regains activity (ivosidenib mechanism steps). TET2 itself has no drug in the corpus.
- Clonal haematopoiesis of indeterminate potential
- IDH-mutant AML (TET2 inhibited by 2-hydroxyglutarate)
- Follicular helper T-cell lymphomas with TET2 and DNMT3A mutations
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"TET2" OR ABSTRACT:"TET2" OR TITLE:"KIAA1546" OR ABSTRACT:"KIAA1546" OR TITLE:"tet methylcytosine dioxygenase 2" OR ABSTRACT:"tet methylcytosine dioxygenase 2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TET2, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tet2.json. Licence CC BY-NC 4.0.